We Design
We apply our unique collective expertise to design small molecule therapeutics.
We push the leading edge to solve drug discovery’s big challenges.
We strive to develop meaningful medicines for patients.

Over more than a decade of pioneering technologically-driven methods of drug discovery, Nimbus has used cutting-edge tools to make therapeutic progress against the most challenging of targets — successfully drugging the undruggable, mapping the uncrystallizable and advancing multiple innovative therapeutics to the clinic.

Nimbus Leadership

Erin Cowhig

Chief People Officer

Scott Edmondson

Senior Vice President, Head of Chemistry

Zak Huang

Vice President, Regulatory Affairs

Abbas Kazimi

Chief Business Officer

Jeb Keiper

Chief Executive Officer

Christine Loh

Senior Vice President, Head of Biology

Avinash Phadke
Avinash Phadke

Vice President, Head of CMC

Gabrielle Poirier

Vice President, Clinical Operations

Ian Sanderson
Ian Sanderson

Chief Financial Officer

Bhaskar Srivastava
Bhaskar Srivastava
M.D., Ph.D.

Senior Vice President, Clinical Development

Peter J. Tummino

Chief Scientific Officer

Holly Whittemore

Chief Accounting Officer

Board of Directors

Bruce Booth, Ph.D.

General Partner, Atlas Venture

Read bio
Jean George, MBA

General Partner, Lightstone Ventures

Read bio
Laura Stoppel, Ph.D.

Principal, RA Capital Management

Read bio
Rajeev Dadoo, Ph.D., MBA

Partner, SR One Ltd.

Read bio
Anne McGeorge, M.S., CPA

Operating Partner , Havencrest Healthcare Partners

Read bio
Mark Iwicki

Chairman and CEO, Kala Pharmaceuticals

Read bio
Sam Huang

Principal, BVF Partners L.P.

Read bio
Jeb Keiper, M.S., MBA

CEO, Nimbus Therapeutics

Read bio
George P. Vlasuk, Ph.D.

Board Director, former President, CEO, CSO, Navitor Pharmaceuticals

Read bio


Nimbus Therapeutics is backed by world-class life science investors, including those listed below and others. The company closed a $24 million Series A financing in June 2011, a $43 million Series B financing in March 2015, an additional $65 million in financing in June 2018, $60 million in financing in October 2020, and $105 million in financing in July 2021.